報價延遲最少15分鐘:2025/07/20 09:20 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.585 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.83/-0.77
|
|
企業價值
48.59M
|
| 資產負債 |
|
每股賬面淨值
0.19
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/20 09:20 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates inSwitzerland, Spain, the United States, and Australia. |
